Research programme: adenosine analogues - Purnovate
Latest Information Update: 24 May 2022
At a glance
- Originator Purnovate
- Developer ADial Pharmaceuticals; Purnovate; University of California, San Diego
- Class Anti-infectives; Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Drug withdrawal therapies; Non-opioid analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Pain
- Research Asthma; Cancer; Cocaine-related disorders; Diabetes mellitus; Infections; Inflammation; Inflammatory bowel diseases
Most Recent Events
- 19 May 2022 Adial Pharmaceuticals enters into research agreement with the Medical College of Wisconsin to evaluate adenosine analogs in diabetes and non-alcoholic steatohepatitis
- 19 May 2022 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
- 04 May 2022 Purnovate enteres into a Research collaboration agreement with the University of California San Diego to evaluate Adenosine analogs for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases